

Retina CI Review


February 2019

Novartis Exhibit 2167.001
Regeneron v. Novartis, IPR2021-00816

Agenda

1. Retina Landscape
2. Aflibercept (Regeneron)
3. Ranibizumab (Roche/Genentech)
4. Abicipar (Allergan)
5. Conbercept (Kanghong)
6. Retina Biosimilar Landscape

Novartis Pharmaceuticals | Ophthalmology
2 Business Use Only



Retina Landscape

Novartis Exhibit 2167.003
Regeneron v. Novartis, IPR2021-00816

Competition generating interest outside “ability to dry”

NVS

Market Reception

Key Data and Timing

Company Product

Regeneron	Eylea	<ol style="list-style-type: none"> VIEW extension: Q12 Y2 PDUFA Aug '18 ARIES Ph4: Early vs late T&E with fixed Q12 arm, readout 1H 2019 DR Indication PDUFA May 13, 2019 Pre-filled syringe launch later in 2019 after 1H19 resubmission of Prior-Approval Supplement More concentrated dose 	<ol style="list-style-type: none"> Facilitates T&E adopters Access to broader patient population Now just as convenient as Lucentis Brolucizumab parity expected
Genentech	Port Delivery System	LADDER Ph2: median 15 months between refills, Ph3 initiated, first readouts throughout 2019	Addressing largest unmet need from the market, game-changing innovation
Chengdu Kanghong	Conbercept	PANDA Ph3: Q12 and Q8 fixed dosing results expected 2H 2019	Ability to offer low branded price before entry of biosimilars due to limited R&D spend to date
Roche	Faricimab (RG7716)	AVENUE / STAIRWAY Ph2: Hth RBZ 36w endpoint with extended durability	Non-contender without significant BCVA superiority
Allergan	Abicipar Pegol (DARPin)	CEDAR / SEQUOIA Ph3: Q12 fixed dosing possible but poor efficacy and >15% inflammation	Inflammation rates unsustainable without reformulation

Novartis Pharmaceuticals | Ophthalmology
4 Business Use Only

Retina Landscape Estimated Approval Timeline

Key Competitors
 Anti-VEGFs
 PDGFs (single/ combination)
 Steroids
 Exploratory MOA

2018 2019 2020 2021 2022 2023 2024 2025



Last Update: Feb19

Novartis Pharmaceuticals | Ophthalmology
5 Business Use Only

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.